GSA Capital Partners’s Sagimet Biosciences SGMT Stock Holding History

GSA Capital Partners’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$73K	Sell	13,992 -11,204	-44%	-$62.4K	﹤0.01%	1587
2025 Q4	$149K	Sell	25,196 -60,052	-70%	-$431K	0.01%	1479
2025 Q3	$585K	Buy	+85,248	New	+$691K	0.05%	742
2025 Q2	–	Sell	-28,930	Closed	-$94K	–	2103
2025 Q1	$94K	Sell	28,930 -53,250	-65%	-$223K	0.01%	1511
2024 Q4	$370K	Buy	+82,180	New	+$416K	0.03%	1094
2024 Q2	–	Sell	-16,452	Closed	-$89K	–	1984
2024 Q1	$89K	Buy	+16,452	New	+$118K	0.01%	1500

Other funds holding SGMT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GSA Capital Partners's SGMT Position: Q1 2026 in Review

GSA Capital Partners reduced its Sagimet Biosciences (SGMT) stake by 44% in Q1 2026, selling an estimated $62.4K and leaving 13,992 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #1587.

GSA Capital Partners first reported a position in SGMT in Q1 2024 and has held it in 6 quarters since. The position peaked at $585K in Q3 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

GSA Capital Partners held 13,992 shares of Sagimet Biosciences worth $73K as of Q1 2026.
GSA Capital Partners sold 11,204 Sagimet Biosciences shares in Q1 2026, an estimated $62.4K.
Sagimet Biosciences made up ﹤0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1587 holding.
GSA Capital Partners first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 6 quarters since.
GSA Capital Partners's Sagimet Biosciences position peaked at $585K in Q3 2025.
88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.